Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Edwards Lifesciences (NY: EW )

67.54 +0.53 (+0.79%)
Official Closing Price Updated: 7:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Edwards Lifesciences

< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
eBay To Rally Around 30%? Here Are 10 Other Analyst Forecasts For Tuesday
B of A Securities cut the price target for Catalent, Inc. (NYSE: CTLT) from $78 to $49. B of A Securities analyst Derik De Bruin maintained a Neutral rating. Catalent shares fell 0.2% to $44.83 in... 
Via Benzinga
The Latest Analyst Ratings for Edwards Lifesciences
Via Benzinga
Here's How Much You Would Have Made Owning Edwards Lifesciences Stock In The Last 5 Years
Via Benzinga
3 No-Brainer Medical Device Stocks to Buy Right Now
These companies have consistently delivered revenue and EPS gains. 
Via The Motley Fool
The Latest Analyst Ratings for Edwards Lifesciences
Via Benzinga
Looking Into Edwards Lifesciences's Recent Short Interest
Via Benzinga
Expert Ratings for Edwards Lifesciences
Via Benzinga
Edwards Lifesciences Stock Jumps After Beating Fourth-Quarter Views
The company expects full-year sales to grow 9%-12% in constant currency. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For March 29, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 8, 2023
Via Benzinga
Here's How Much $1000 Invested In Edwards Lifesciences 10 Years Ago Would Be Worth Today
Via Benzinga
What 8 Analyst Ratings Have To Say About Edwards Lifesciences
Via Benzinga
A Preview Of Edwards Lifesciences's Earnings
Via Benzinga
Interview With David Rolfe of Wedgewood Partners
Motley Fool analyst John Rotonti recently seized the opportunity to interview David Rolfe. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For February 6, 2023
Via Benzinga
Expert Ratings for Edwards Lifesciences
Via Benzinga
15 Analysts Have This to Say About Edwards Lifesciences
Via Benzinga
Buy/Sell: Wall Street's Top 10 Stock Calls This Week - Saturday, Feb. 4
What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street’s best analysts during the week of Jan. 30 through Feb. 3. 
Via Talk Markets
Edwards Lifesciences Q4 Earnings Beats Street Estimates, Expects Easing Of Macro Headwinds Later In 2023
Via Benzinga
2 Top Dividend Growth Stocks to Buy in February
They don't offer the highest yields, but these strongly profitable businesses are poised to raise their payouts at a blistering pace. 
Via The Motley Fool
Amazon To Rally Around 29%? Here Are 10 Other Analyst Forecasts For Monday
Barclays cut the price target for Amazon.com, Inc. (NASDAQ: AMZN) from $140 to $130. Barclays analyst Ross Sandler maintained an Overweight rating. Amazon shares fell 1.2% to $101.06 in pre-market... 
Via Benzinga
2 Smartest Tech Stocks to Buy in 2022 and Beyond
The tech space is still bursting with opportunities for long-term investors. 
Via The Motley Fool
Earnings Scheduled For January 31, 2023
Companies Reporting Before The Bell • Biophytis (NASDAQ:BPTS) is projected to report earnings for its first quarter. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 30, 2023
Via Benzinga
Jim Cramer Recommends These 5 Healthcare Stocks For 2023: 'Biggest Winners Were Boring, Consistent Operators'
Prominent market commentator Jim Cramer has recommended five healthcare stocks which he believes should be on investors’ shopping list for 2023. 
Via Benzinga
JPMorgan To Rally Around 17%? Here Are 10 Other Price Target Changes For Tuesday
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 6, 2022
Via Benzinga
Reata Pharmaceuticals To Jump 220%? Plus JP Morgan Predicts $51 For Las Vegas Sands
Goldman Sachs boosted the price target on Reata Pharmaceuticals, Inc. (NASDAQ: RETA) from $86 to $115. Goldman Sachs analyst Madhu Kumar maintained the stock with a Buy rating. Reata Pharmaceuticals... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 2, 2022
Via Benzinga
< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.